The Biotechnology Sector is Currently the Strongest Sector in the Pharmaceutical Market, With a More Positive Outlook Than Pharma, Speciality Pharma and Generics Predicted
Posted on: Thursday, 3 November 2005, 09:01 CST
Research and Markets (http://www.researchandmarkets.com/reports/c27023) has announced the addition of The Biotechnology Market Outlook: Growth Opportunities and Effective Strategies for Licensing and Collaborations to their offering
In 1982 the US Food and Drug Administration (FDA) approved the first biotech drug, human insulin, which was produced in genetically modified bacteria; since Genentech went public back in 1980 the biotech sector has been marked by periodic boom-and-bust cycles in the stock market. The reason for the volatility of the sector is due to the nature of the field, which holds great promise and yet requires enormous risk-taking. These boom-and-bust cycles may never end, but they could be moderating, primarily because biotechnology is maturing.
The biotech sector has shown rapid growth in the last 5 years, with global revenues rising from $22.7bn in 2000 to $44.3bn in 2004. This is currently the strongest growth sector in the pharmaceutical market. 47% of industry executives surveyed for this report believed that the biotech sector would show an annual growth of greater than 10% over the next 5 to 10 years, while a further 35% of those surveyed indicated a growth rate of 6-10% to be most accurate. Overall, the biotech sector has a more positive outlook than pharma, specialty pharma and generics.
Although the biotech sector remains a relatively small proportion of the total drug market (8% globally in 2004), approximately 27% of new medicines in active development are now biotech products. However, a large proportion of these are in preclinical trials, so there is still a large risk associated with the developments of these compounds. The gap in small molecule drug approvals versus biological approvals is reducing year-on-year. In 2004, 11 of the 76 blockbuster products were biologicals, and there are several other products (Humira, Rebif, Avastin and Erbitux) that are forecast to attain blockbuster status by 2005.
'The Biotechnology Market Outlook' looks at the following key topics:
- Biotechnology industry status
- The biotechnology market
- Drivers and resistors of market growth
- Biotech growth strategies
- Changing relationship between pharma & biotech
For more information visit http://www.researchandmarkets.com/reports/c27023
Source: Business Wire
Related Articles
- Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
- Curis to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
- Genaera Corporation to Present at CIBC World Markets Annual Biotechnology & Specialty Pharma Conference
- Curis to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
- Research and Markets: Worldwide Prescription Drug Market for Women's Health Forecast to Grow to $11.6 Billion in 2009
- China Industry Outlook: Computer Products Report Shows Computer Makers Expect Sales to Grow By 40 Percent to US$139 Billion in 2005
- Study: Growth in U.S. Drug Sales at 9-Year Low
- Fujitsu Siemens Computers Outperforms Market Growth
- EU Says Biotech Sector At Risk Over Funds
 |
 |
User Comments (0)
RSS Feeds